Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.67 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3877004 | 0.80 | GRM5 (1.00) | GRM5CA12CA1CA2CA9 | |
| SCHEMBL3881087 | 0.80 | GRM5 (0.70) | GRM5ABL1SLC6A2 | |
| SCHEMBL3871676 | 0.80 | GRM5 (0.70) | GRM5SLC6A2 | |
| Hydrochloric Acid SCHEMBL4654166 | 0.79 | GRM5 (0.97) | GRM5CA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL3876458 | 0.79 | GRM5 (0.68) | GRM5SLC6A2 | |
| Hydrochloric Acid SCHEMBL3881392 | 0.79 | GRM5 (0.68) | GRM5ABL1SLC6A2 | |
| SCHEMBL3872323 | 0.79 | GRM5 (0.68) | GRM5SLC6A2 | |
| Hydrochloric Acid SCHEMBL3879152 | 0.77 | GRM5 (0.66) | GRM5SLC6A2 | |
| M-Mpep SCHEMBL29393403 | 0.77 | GRM5 (1.00) | GRM5 | |
| M-Mpep SCHEMBL1020513 | 0.77 | GRM5 (1.00) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2028180-A1 | Novel aminopyridine derivatives as mGluR5 antagonists | ADDEX Pharma S.A. (CH) | 2009-02-25 | — | — | EP | claimed |
| EP-1603877-B1 | NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS | ADDEX PHARMA SA (CH) | 2008-11-26 | — | — | EP | claimed |
| US-20080004316-A1 | Novel aminopyridine derivatives as mGluR5 antagonists | ADDEX PHARMACEUTICALS SA (CH) | 2008-01-03 | — | — | US | claimed |
| US-7205411-B2 | Aminopyridine derivatives as mGluR5 antagonists | ADDEX PHARMACEUTICALS SA (CH) | 2007-04-17 | — | — | US | claimed |
| US-20060030601-A1 | Novel aminopyridine derivatives as mGluR5 antagonists | ADDEX PHARMACEUTICALS SA (CH) | 2006-02-09 | — | — | US | claimed |
| EP-1603877-A1 | NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS | Addex Pharmaceuticals SA (CH) | 2005-12-14 | — | — | EP | claimed |
| WO-2004078728-A1 | NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS | ADDEX PHARMACEUTICALS SA (CH) | 2004-09-16 | — | — | WO | claimed |
| EP-2028180-A1 | Novel aminopyridine derivatives as mGluR5 antagonists | ADDEX Pharma S.A. (CH) | 2009-02-25 | — | — | EP | disclosed |
| EP-1603877-B1 | NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS | ADDEX PHARMA SA (CH) | 2008-11-26 | — | — | EP | disclosed |
| US-20080004316-A1 | Novel aminopyridine derivatives as mGluR5 antagonists | ADDEX PHARMACEUTICALS SA (CH) | 2008-01-03 | — | — | US | disclosed |
| US-7205411-B2 | Aminopyridine derivatives as mGluR5 antagonists | ADDEX PHARMACEUTICALS SA (CH) | 2007-04-17 | — | — | US | disclosed |
| US-20060030601-A1 | Novel aminopyridine derivatives as mGluR5 antagonists | ADDEX PHARMACEUTICALS SA (CH) | 2006-02-09 | — | — | US | disclosed |
| EP-1603877-A1 | NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS | Addex Pharmaceuticals SA (CH) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004078728-A1 | NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS | ADDEX PHARMACEUTICALS SA (CH) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004316-A1 | Novel aminopyridine derivatives as mGluR5 antagonists | GRM5, GRM6, GRM2 | GRM5 1/4885CA12 4868/4885CA1 4379/4885 |
| US-20060030601-A1 | Novel aminopyridine derivatives as mGluR5 antagonists | GRM5, GRM6, GRM2 | GRM5 1/4885CA12 4868/4885CA1 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.